Our Group organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Scientific Research

Pi3k Pathway-Specific Inhibitors: New Hope for Patients with Er-Positive or Her2-Positive Breast Cancers

The De’s laboratory seeks to investigate tumor suppressor and oncogene signaling pathways that are altered in breast tumors using a multidisciplinary approach that includes genetics, biochemistry, bioinformatics, and pathology. As a signal transduction research laboratory, we would like to understand how to phosphorylation and dephosphorylation of cellular proteins results in regulated and coordinated signal relay in ER+ and HER2+ breast cancers include all of the intrinsic molecular subtype. Furthermore, we are interested how the different oncogenic signaling pathways interact to dysregulate cell signaling (otherwise in fine tuned) in the context of genetic influences or when other membrane receptor tyrosine kinases are activated at the same time. READ MORE

  • Share this page
  • Facebook
  • Twitter
  • LinkedIn
  • Google+
  • Pinterest
  • Blogger
Top